Abacavir use and risk of recurrent myocardial infarction. AIDS
Sabin et al. on behalf of the D:A:D study group aimed to investigate the association between abacavir use and subsequent myocardial infarction risk among the patients who had already experienced an myocardial infarction during prospective D:A:D follow-up.
Nine-hundred-eighty-four individuals experienced an index myocardial infarction during the study (91.3% male, median age 51 at index myocardial infarction). Over 5’312 person-years of follow-up, there were 136 recurrent myocardial infarctions (rate 2.56/100 person-years, 95% confidence interval 2.13–2.99).
Rates were:
– 2.40 (1.71–3.09) and 2.65 (2.10–3.21)/100 person-years in those who were and were not on abacavir, respectively, at the index myocardial infarction,
– 2.90 (2.01– 3.78) and 2.44 (1.95–2.93)/100 person-years in those who were and were not currently receiving abacavir, respectively, post-myocardial infarction.
No association was seen with recurrent myocardial infarction and either cumulative exposure to abacavir [relative rate 0.86 (0.68–1.10)/5 years], receipt of abacavir at index myocardial infarction [0.90 (0.63–1.29)] nor recent post-myocardial infarction exposure to abacavir [1.19 (0.82–1.71)].
In summary, among people with a previous myocardial infarction, there was no evidence for an association between use of abacavir post-myocardial infarction and an elevated risk of a recurrent myocardial infarction.